Hangzhou Tigermed Consulting Co (HKSE:03347) Marketable Securities : HK$182 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Hangzhou Tigermed Consulting Co Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Hangzhou Tigermed Consulting Co's Marketable Securities for the quarter that ended in Mar. 2025 was HK$182 Mil.

Hangzhou Tigermed Consulting Co's annual Marketable Securities increased from Dec. 2022 (HK$28 Mil) to Dec. 2023 (HK$46 Mil) and increased from Dec. 2023 (HK$46 Mil) to Dec. 2024 (HK$80 Mil).

Hangzhou Tigermed Consulting Co Marketable Securities Historical Data

The historical data trend for Hangzhou Tigermed Consulting Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Tigermed Consulting Co Marketable Securities Chart

Hangzhou Tigermed Consulting Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

30.82

35.73

27.86

46.09

79.92

Hangzhou Tigermed Consulting Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Marketable Securities	Get a 7-Day Free Trial															9.45	45.77	84.01	79.92	182.28

Hangzhou Tigermed Consulting Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Hangzhou Tigermed Consulting Co (HKSE:03347) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Hangzhou Tigermed Consulting Co Marketable Securities Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hangzhou Tigermed Consulting Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (HKSE:03347) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

5HZ1:Germany 300347:China

Address

Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053

Website

https://www.tigermed.net

Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.

Executives

Sands Capital Management, Llc	2101 Beneficial owner
Sands Capital Management, Lp	2201 Interest of corporation controlled by you
Sands Family Trust, Llc	2201 Interest of corporation controlled by you
Sands Frank Melville Jr.	2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
F-j Sands Family I, Llc	2201 Interest of corporation controlled by you
2017 Eagle Holdings Llc	2201 Interest of corporation controlled by you
Citigroup Inc.	2201 Interest of corporation controlled by you
Ubs Group Ag	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co.	2502 Approved lending agent
Ninety One Plc/ Ninety One Ltd	2102 Investment manager
Ninety One Uk Limited	2102 Investment manager
Baillie Gifford & Co	2102 Investment manager

Hangzhou Tigermed Consulting Co Headlines

No Headlines